Abacavir contraindications: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 5: | Line 5: | ||
==Contraindications== | ==Contraindications== | ||
ZIAGEN is contraindicated in patients with: | |||
* Previously demonstrated hypersensitivity to abacavir or any other component of the products. | |||
: | : NEVER restart ZIAGEN or any other abacavir-containing product following a [[hypersensitivity]] reaction to abacavir, regardless of [[HLA]]-B*5701 status. | ||
* Moderate or severe hepatic impairment [see Dosage and Administration].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ZIAGEN (ABACAVIR SULFATE) TABLET, FILM COATED ZIAGEN (ABACAVIR SULFATE) SOLUTION [VIIV HEALTHCARE COMPANY] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ca73b519-015a-436d-aa3c-af53492825a1 | publisher = | date = | accessdate = 30 December 2013 }}</ref> | |||
==References== | ==References== | ||
Revision as of 02:49, 5 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Contraindications
ZIAGEN is contraindicated in patients with:
- Previously demonstrated hypersensitivity to abacavir or any other component of the products.
- NEVER restart ZIAGEN or any other abacavir-containing product following a hypersensitivity reaction to abacavir, regardless of HLA-B*5701 status.
- Moderate or severe hepatic impairment [see Dosage and Administration].[1]
References
- ↑ "ZIAGEN (ABACAVIR SULFATE) TABLET, FILM COATED ZIAGEN (ABACAVIR SULFATE) SOLUTION [VIIV HEALTHCARE COMPANY]". Retrieved 30 December 2013.
Adapted from the FDA Package Insert.